| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |